Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
AVTX Stock Chart & Stats
$18.55
-$0.55(-7.32%)
At close: 4:00 PM EST
$18.55
-$0.55(-7.32%)
Day’s Range― - ―
52-Week Range$3.39 - $19.41
Previous CloseN/A
Volume10.82K
Average Volume (3M)396.58K
Market Cap
$336.39M
Enterprise Value$68.79M
Total Cash (Recent Filing)$111.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Mar 26, 2026EPS Estimate
-1.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding18,133,968
10 Day Avg. Volume383,141
30 Day Avg. Volume396,584
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)136.95
P/FCF Ratio-1.23
Enterprise Value/Market Cap0.20
Enterprise Value/Revenue358.30
Enterprise Value/Gross Profit655.18
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$37.00Price Target Upside99.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enrolled.
Market PotentialThe large, underpenetrated HS market with high-growth potential offers room for multiple advanced therapies, including AVTX-009, to be commercially successful.
Therapeutic AdvantageAVTX-009's focus on IL-1β gives it an advantage over therapies that also target IL-1α, offering a mechanistic precision with higher affinity and longer half-life.
Bears Say
Development RisksRisks include delays in clinical development, negative clinical data, failure to achieve approval, slower-than-anticipated commercial uptake, and possible dilution risk.
Avalo Therapeutics News
AVTX FAQ
What was Avalo Therapeutics’s price range in the past 12 months?
Avalo Therapeutics lowest stock price was $3.39 and its highest was $19.41 in the past 12 months.
What is Avalo Therapeutics’s market cap?
Avalo Therapeutics’s market cap is $336.39M.
When is Avalo Therapeutics’s upcoming earnings report date?
Avalo Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 117 days.
How were Avalo Therapeutics’s earnings last quarter?
Avalo Therapeutics released its earnings results on Nov 06, 2025. The company reported -$2.19 earnings per share for the quarter, missing the consensus estimate of -$1.658 by -$0.532.
Is Avalo Therapeutics overvalued?
According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued.
Does Avalo Therapeutics pay dividends?
Avalo Therapeutics does not currently pay dividends.
What is Avalo Therapeutics’s EPS estimate?
Avalo Therapeutics’s EPS estimate is -1.52.
How many shares outstanding does Avalo Therapeutics have?
Avalo Therapeutics has 18,133,968 shares outstanding.
What happened to Avalo Therapeutics’s price movement after its last earnings report?
Avalo Therapeutics reported an EPS of -$2.19 in its last earnings report, missing expectations of -$1.658. Following the earnings report the stock price went down -6.261%.
Which hedge fund is a major shareholder of Avalo Therapeutics?
Currently, no hedge funds are holding shares in AVTX
Avalo Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.00 (99.46% Upside)
$37.00 (99.46% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 270.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $162.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.68%
12-Months-Change
Fundamentals
Return on Equity
-174.79%
Trailing 12-Months
Asset Growth
27.06%
Trailing 12-Months
Company Description
Avalo Therapeutics
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
AVTX Stock 12 Month Forecast
Average Price Target
$37.00
▲(99.46% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Fractyl Health, Inc.
―